Suppr超能文献

C-X-C 基序趋化因子配体 12(CXCL12)/C-X-C 基序趋化因子受体 7(CXCR7)通过激活信号转导和转录激活因子 3(STAT3)通路调节上皮-间充质转化过程,并促进食管癌的转移。

C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway.

机构信息

Department of Thoracic Surgery, Ningbo First Hospital, Ningbo, Zhejiang province, China.

出版信息

Bioengineered. 2022 Mar;13(3):7425-7438. doi: 10.1080/21655979.2022.2048984.

Abstract

Esophageal cancer is a malignant tumor of the digestive system that is prone to metastasis. Chemokines and their receptors act an essential role in the occurrence and development of tumors. Here, we investigated the regulatory mechanism of CXCL12/CXCR7 in the growth and metastasis of esophageal cancer. CXCR7 was found highly expressed in clinical tissues and cells of esophageal cancer. Knockdown of CXCR7 inhibited the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) process of esophageal cancer cells. The knockdown of chemokine CXCL12 also inhibited the expression of EMT-related proteins and the mesenchymal morphology changes of esophageal cancer cells, but the knockdown of C-X-C motif chemokine receptor 4 (CXCR4) had no such effect. Furthermore, the knockdown of CXCR7 attenuated the enhanced EMT process induced by CXCL12 overexpression, while the knockdown of CXCR4 cannot inhibit this process. In addition, overexpressed CXCL12/CXCR7 activated the downstream STAT3 pathway, but had little effect on the extracellular regulated protein kinase (ERK) or serine-threonine kinase (AKT) pathways. Inhibition of the STAT3 pathway using AZD9150 weakened the accelerated effects of CXCL12/CXCR7 on the growth and metastasis of esophageal cancer in vitro and in vivo. In conclusion, our research revealed that CXCL12/CXCR7 regulates EMT and other malignant processes by activating the STAT3 pathway to accelerate the growth and metastasis of esophageal cancer.

摘要

食管癌是一种消化系统的恶性肿瘤,容易发生转移。趋化因子及其受体在肿瘤的发生和发展中起着重要作用。在这里,我们研究了 CXCL12/CXCR7 在食管癌生长和转移中的调节机制。发现 CXCR7 在食管癌的临床组织和细胞中高度表达。敲低 CXCR7 抑制了食管癌细胞的增殖、迁移、侵袭和上皮-间充质转化(EMT)过程。趋化因子 CXCL12 的敲低也抑制了 EMT 相关蛋白的表达和食管癌细胞的间质形态变化,但 C-X-C 基序趋化因子受体 4(CXCR4)的敲低没有这种作用。此外,敲低 CXCR7 减弱了 CXCL12 过表达诱导的增强的 EMT 过程,而敲低 CXCR4 不能抑制该过程。此外,过表达的 CXCL12/CXCR7 激活了下游 STAT3 通路,但对细胞外调节蛋白激酶(ERK)或丝氨酸-苏氨酸激酶(AKT)通路几乎没有影响。使用 AZD9150 抑制 STAT3 通路减弱了 CXCL12/CXCR7 在体外和体内对食管癌生长和转移的加速作用。总之,我们的研究表明,CXCL12/CXCR7 通过激活 STAT3 通路调节 EMT 和其他恶性过程,从而加速食管癌的生长和转移。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8973702/316609cded13/KBIE_A_2048984_UF0001_OC.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验